Mesoblast Ltd ADR (MESO)

$6.22 0.22 (3.67%)

16:00 EDT MESO Stock Quote Delayed 30 Minutes

Feeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025

By Alex Sirois, InvestorPlace Contributor Apr 3, 2024

Aggressive stocks to 10X returns call to investors, with the promise of reaching those heights and beyond by 2025.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 4.05B

PE Ratio -

EPS -

Volume (Avg. Vol.) 199,269

Day's Range $5.82 - $6.24

52-Week Range $0.97 - $7.36

Dividend & Yield N/A (N/A)

MESO Stock Predictions, Articles, and Mesoblast Ltd ADR News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Mar 8, 2023

We're getting into the biggest pre-market stock movers traders will want to keep an eye on Wednesday with the latest news!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jul 19, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Dec 15, 2021

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

Mesoblast gets FDA orphan drug status for Revascor (NASDAQ:MESO)

From Seeking Alpha Feb 15, 2024

Mesoblast's (MESO) cell therapy, Revascor, receives orphan drug designation from the FDA for treating hypoplastic left heart syndrome in children. Read more here.

Mesoblast cell therapy gets FDA rare pediatric disease designation (NASDAQ:MESO)

From Seeking Alpha Jan 19, 2024

Mesoblast's shares surge 12% after receiving a rare pediatric disease designation from the FDA for its allogeneic cell therapy Revascor, showing promising...

Why Shares of Mesoblast Are Down Monday

From The Motley Fool Aug 7, 2023

The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.

Why Shares of Mesoblast Are Plunging Friday

From The Motley Fool Aug 4, 2023

The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.

Mesoblast stock down as William Blair downgrades on FDA snub

From Seeking Alpha Aug 4, 2023

Mesoblast (MESO) continued to fall in the morning hours Friday as William Blair downgraded it on FDA rejection of its cell therapy remestemcel-L. Read more here.

Chardan Capital Sticks to Its Sell Rating for Mesoblast (MESO)

From TipRanks Nov 23, 2022

In a report released today, Keay Nakae from Chardan Capital maintained a Sell rating on Mesoblast (MESO – Research Report), with a price target of $2.50. The ...

ADVERTISEMENT